Journal
ANTIVIRAL RESEARCH
Volume 97, Issue 2, Pages 169-179Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2012.12.002
Keywords
Flavivirus; Yellow fever virus; Antiviral therapy
Categories
Funding
- NIAID NIH HHS [HHSN272201000039I] Funding Source: Medline
Ask authors/readers for more resources
A number of viruses in the family Flaviviridae are the focus of efforts to develop effective antiviral therapies. Success has been achieved with inhibitors for the treatment of hepatitis C, and there is interest in clinical trials of drugs against dengue fever. Antiviral therapies have also been evaluated in patients with Japanese encephalitis and West Nile encephalitis. However, no treatment has been developed against the prototype flavivirus, yellow fever virus (YFV). Despite the availability of the live, attenuated 17D vaccine, thousands of cases of YF continue to occur each year in Africa and South America, with a significant mortality rate. In addition, a small number of vaccinees develop severe systemic infections with the 17D virus. This paper reviews current efforts to develop antiviral therapies, either directly targeting the virus or blocking detrimental host responses to infection. (c) 2013 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available